Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Agile Therapeutics Inc    AGRX

AGILE THERAPEUTICS INC (AGRX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/17/2018 10/18/2018 10/19/2018 10/22/2018 10/23/2018 Date
0.89(c) 0.8352(c) 0.9552(c) 0.81(c) 0.71011 Last
4 248 468 2 669 547 5 565 240 3 695 125 1 931 098 Volume
-9.07% -6.16% +14.37% -15.20% -12.33% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -22,8 M
Net income 2018 -23,3 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -25,4 M
Net income 2019 -23,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 27,8 M
More Financials
Company
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch for use in contraception.It offers its product candidate Twirla, which is an investigational non-daily prescription contraceptive.The company was founded by Chien Te Yen on... 
More about the company
Surperformance© ratings of Agile Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on AGILE THERAPEUTICS INC
10/19MICROSOFT : Shining the Light on Microsoft Corporation (Msft) and Agile Therapeu..
AQ
10/09Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the..
GL
10/05AGILE THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form 8..
AQ
08/14Agile Therapeutics Inc (AGRX) Holdings Cut by Russell Investments Group Ltd.
AQ
08/09AGILE THERAPEUTICS : Reports Second Quarter 2018 Financial Results
AQ
08/03AGILE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
08/03AGILE THERAPEUTICS INC : Results of Operations and Financial Condition, Financia..
AQ
08/03AGILE THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/03Agile Therapeutics Reports Second Quarter 2018 Financial Results
GL
07/26AGILE THERAPEUTICS : FDA's Office of Drug Evaluation III Denies Agile Therapeuti..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/21Roche takes on Loxo, Bayer in gene-defined cancer class
RE
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/19$EARS $AGRX big moves $FLKS is STILL RED but not for long BUY! 
10/19$FLKS add for a bounce to 70-80c on $EARS and $AGRX bounces, they ran in tand.. 
10/17$TTNP under 25c is like buying $FLKS at 45c b4 it tripled, $AGRX at 25c befor..
2
10/16Analysts Set Agile Therapeutics Inc $AGRX Target Price at $4.00  
10/16Thinking about buying stock in Agile Therapeutics, Advanced Micro Devices, Au.. 
More tweets
Qtime:20
News from SeekingAlpha
10/09Agile Therapeutics up 62% on development path for Twirla 
09/11Agile Therapeutics up 55% premarket 
08/03Agile Therapeutics beats by $0.01 
07/24FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours 
06/15An Update On Corium International 
Chart AGILE THERAPEUTICS INC
Duration : Period :
Agile Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 3,00 $
Spread / Average Target 270%
EPS Revisions
Managers
NameTitle
Alfred F. Altomari Chairman & Chief Executive Officer
Scott M. Coiante Senior VP, Chief Financial & Accounting Officer
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer & Senior Vice President
Abhijeet J. Lele Lead Independent Director
William T. McKee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AGILE THERAPEUTICS INC-69.89%29
GILEAD SCIENCES0.98%96 150
VERTEX PHARMACEUTICALS18.38%45 720
REGENERON PHARMACEUTICALS3.69%41 951
NEUROCRINE BIOSCIENCES, INC.40.70%10 366
SAREPTA THERAPEUTICS INC138.25%9 222